<DOC>
	<DOCNO>NCT00984620</DOCNO>
	<brief_summary>To compare antiviral efficacy safety 12-week 24-week treatment BI 201335 dose 120 mg daily , 24-week background pegylated interferon-alpha 2a ( PegIFN ) plus ribavirin ( RBV ) , treatment-naïve patient infect hepatitis C virus ( HCV ) genotype 1</brief_summary>
	<brief_title>Short Term Treatment With BI 201335 , Peginterferon-alpha 2a Ribavirin Hepatitis c Virus Genotype-1 Treatment-naïve Patients ( SILEN-C3 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Inclusion criterion : 1 . Chronic hepatitis C infection genotype 1 2 . Therapynaïve interferon , pegylated interferon , ribavirin 3 . HCV viral load &gt; 100.000 IU/ml screen 4 . Liver biopsy fibroscan within two year prior screen provide evidence degree fibrosis cirrhosis 5 . Normal retinal finding fundoscopy within 6 month prior Day 1 6 . Age 18 70 year Exclusion criterion : 1 . HCV mixed genotype ( 1/2 , 1/3 , 1/4 ) . 2 . Patients previously treat least one dose protease inhibitor 3 . Evidence liver disease due cause chronic HCV infection 4 . Positive HIV1 HIV2 antibodies 5 . Hepatitis B virus ( HBV ) infection 6 . Decompensated liver disease , history decompensated liver disease 7 . Active malignancy history malignancy within last 5 year 8 . History alcohol drug abuse ( except cannabis ) within past 12 month . 9 . Body Mass Index &lt; 18 &gt; 35 kg/m2 . 10 . Usage investigational drug within 30 day prior enrolment 11 . Alpha fetoprotein value &gt; 100ng/mL screening ; 12 . Total bilirubin &gt; 1.5 x ULN ratio direct/indirect &gt; 1 . 13 . ALT AST level &gt; 10 x ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>